Could agomelatine be the ideal antidepressant?

References

• Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry64, 1465–1475 (2003).
   PubMed Web of Science ®Google Scholar
• Depression and Bipolar Support Alliance. The state of depression in America. Executive summary.1–10 (2006).
   Google Scholar
• Lecrubier Y. The burden of depression and anxiety in general medicine. J. Clin. Psychiatry62(Suppl. 8), 4–9 (2001).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA289, 3095–3105 (2003).
   PubMed Web of Science ®Google Scholar
• Zajecka JM. Clinical issues in long-term treatment with antidepressants. J. Clin. Psychiatry61(Suppl. 2), 20–25 (2000).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Anonymous practice guideline for major depressive disorder in adults.Am. J. Psychiatry150, 1–26 (1993).
   PubMed Web of Science ®Google Scholar
• Lecrubier Y. Risk-benefit of newer versus older monoamine oxidase (MAO) inhibitors. Drug Safety16, 374–390 (1997).
   PubMed Web of Science ®Google Scholar
• Richelson E. Pharmacology of antidepressants – characteristics of the ideal drug. Mayo Clin. Proc.69, 1069–1081 (1994).
   PubMed Web of Science ®Google Scholar
• Owens D. New or old antidepressants? Benefits of new drugs are exaggerated. Br. Med. J.309, 1281–1282 (1994).
   PubMed Web of Science ®Google Scholar
• Harrison G. New or old antidepressants? New is better. Br. Med. J.309, 1280–1281 (1994).
   PubMedGoogle Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord.58, 19–36 (2000).
   PubMed Web of Science ®Google Scholar
• Hamrin V, Scahill L. Selective serotonin reuptake inhibitors for children and adolescents with major depression: current controversies and recommendations. Issues Ment. Health Nurs.26, 433–450 (2005).
   PubMedGoogle Scholar
• Spinella M: The Psychopharmacology of Herbal Medicine: Plant Drugs That Alter Mind, Brain, and Behavior. The MIT Press, Cambridge, MA, USA (2001).
   Google Scholar
• Vanderkooy JD, Kennedy SH, Bagby RM. Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Can. J. Psychiatry47, 174–180 (2002).
   PubMed Web of Science ®Google Scholar
• Loo H, Hale A, D’haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int. Clin. Psychopharmacol.17, 239–247 (2002).
   PubMed Web of Science ®Google Scholar
• Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord.18, 289–299 (1990).
   PubMed Web of Science ®Google Scholar
• Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int. Clin. Psychopharmacol.16, 145–151 (2001).
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. Efficacy of selective serotonin reuptake inhibitors (SSRIs) and newer antidepressants in severe depression: Comparison with tricyclic antidepressants (TCAs). J. Clin. Psychiatry60, 326–335 (1999).
   PubMed Web of Science ®Google Scholar
• Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int. Rev. Psychiatry17, 237–245 (2005).
   PubMed Web of Science ®Google Scholar
• Bunney WE, Bunney BG. Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology22, 335–345 (2000).
   PubMed Web of Science ®Google Scholar
• Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int. Clin. Psychopharmacol.21(Suppl. 1), S11–S15 (2006).
   Web of Science ®Google Scholar
• Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin. Neurosci.8(2), 217–226 (2006).
   PubMedGoogle Scholar
• Srinivasan V, Smits M, Spence W et al. Melatonin in mood disorders. World J. Biol. Psychiatry7(3), 138–151 (2006).
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Smits G, Kayumov L et al. Melatonin in circadian rhythm sleep disorders. In: Neuroendocrine Correlates of Sleep/Wakefulness. Cardinali DP, Pandi-Perumal SR (Eds). Springer, New York, NY, USA, 269–294 (2006).
   Google Scholar
• Srinivasan V. Melatonin, biological rhythm disorders and phototherapy. Indian J. Physiol. Pharmacol.41, 309–328 (1997).
   PubMedGoogle Scholar
• Pandi-Perumal SR, Zisapel N, Srinivasan V, Cardinali DP. Melatonin and sleep in aging population. Exp. Gerontol.40, 911–925 (2005).
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Furio AM, Reyes MP, Brusco LI. The use of chronobiotics in the resynchronization of the sleep/wake cycle. Cancer Causes Control17(4), 601–609 (2006).
   PubMed Web of Science ®Google Scholar
• Monti JM, Alvarino F, Cardinali D, Savio I, Pintos A. Polysomnographic study of the effect of melatonin on sleep in elderly patients with chronic primary insomnia. Arch. Gerontol. Geriatr.28, 85–98 (1999).
   PubMed Web of Science ®Google Scholar
• Brzezinski A, Vangel MG, Wurtman RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med. Rev.9, 41–50 (2005).
   PubMed Web of Science ®Google Scholar
• Scheer FA. Potential use of melatonin as adjunct antihypertensive therapy. Am. J. Hypertens.18, 1619–1620 (2005).
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Cannoletta M, Renzi A et al. Prolonged melatonin administration decreases nocturnal blood pressure in women. Am. J. Hypertens.18, 1614–1618 (2005).
   PubMed Web of Science ®Google Scholar
• Dawson D, Armstrong SM. Chronobiotics – drugs that shift rhythms. Pharmacol. Ther.69, 15–36 (1996).
   PubMed Web of Science ®Google Scholar
• Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med. Rev.9, 25–39 (2005).
   PubMed Web of Science ®Google Scholar
• Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog. Neurobiol.56, 359–384 (1998).
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Maestroni GJM, Cardinali DP et al. Melatonin, immune function and aging. Immun. Ageing2, 17 (2005).
   PubMedGoogle Scholar
• Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine27, 101–110 (2005).
   PubMed Web of Science ®Google Scholar
• Srinivasan V. Melatonin, biological rhythm disorders and phototherapy. Indian J. Physiol. Pharmacol.41, 309–328 (1997).
   PubMedGoogle Scholar
• Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA, Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J. Clin. Psychiatry58, 383–388 (1997).
   PubMed Web of Science ®Google Scholar
• Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am. J. Psychiatry155, 1119–1121 (1998).
   PubMed Web of Science ®Google Scholar
• Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J. Psychiatry Neurosci.25, 48–52 (2000).
   PubMed Web of Science ®Google Scholar
• Wirz-Justice A, Graw P, Krauchi K et al. Morning or night-time melatonin is ineffective in seasonal affective disorder. J. Psychiatr. Res.24, 129–137 (1990).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th Edition (DSM-IV). American Psychiatric Press, DC, USA (1994).
   Google Scholar
• Quera-Salva MA, Vanier B, Chapotot F. Effect of agomelatine on the sleep electroencephalogram (EEG) in patients with major depressive disorders (MDD). Eur. Neuropsychopharmacol.15(Suppl. 3), S435 (2005).
   PubMed Web of Science ®Google Scholar
• Lam RW. Sleep disturbances and depression: a challenge for antidepressants. Int. Clin. Psychopharmacol.21(Suppl. 1), S25–S29 (2006).
   PubMed Web of Science ®Google Scholar
• Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med.5, 523–532 (2004).
   PubMed Web of Science ®Google Scholar
• Bogaards JJ, Hissink EM, Briggs M et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur. J. Pharm. Sci.12, 117–124 (2000).
   PubMed Web of Science ®Google Scholar
• Yous S, Andrieux J, Howell HE et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J. Med. Chem.35, 1484–1486 (1992).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Gobert A, Lejeune F et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther.306, 954–964 (2003).
   PubMed Web of Science ®Google Scholar
• Chagraoui A, Protais P, Filloux T, Mocaer E. Agomelatine (S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl.)170, 17–22 (2003).
   PubMed Web of Science ®Google Scholar
• Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci.29, 126–133 (2004).
   PubMed Web of Science ®Google Scholar
• Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int. Clin. Psychopharmacol.21(Suppl. 1), S31–S35 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong SM, McNulty OM, Guardiola-Lemaitre B, Redman JR. Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS). Pharmacol. Biochem. Behav.46, 45–49 (1993).
   PubMed Web of Science ®Google Scholar
• Redman JR, Guardiola-Lemaitre B, Brown M, Delagrange P, Armstrong SM. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms. Psychopharmacology (Berl.)118, 385–390 (1995).
   PubMed Web of Science ®Google Scholar
• Martinet L, Guardiola-Lemaitre B, Mocaer E. Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent. Pharmacol. Biochem. Behav.54, 713–718 (1996).
   PubMed Web of Science ®Google Scholar
• Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J. Biol. Rhythms13, 39–51 (1998).
   PubMed Web of Science ®Google Scholar
• Ying SW, Rusak B, Mocaer E. Chronic exposure to melatonin receptor agonists does not alter their effects on suprachiasmatic nucleus neurons. Eur. J. Pharmacol.342, 29–37 (1998).
   PubMed Web of Science ®Google Scholar
• Weibel L, Turek FW, Mocaer E, Van Reeth O. A melatonin agonist facilitates circadian resynchronization in old hamsters after abrupt shifts in the light-dark cycle. Brain Res.880, 207–211 (2000).
   PubMed Web of Science ®Google Scholar
• Van Reeth O, Weibel L, Olivares E et al. Melatonin or a melatonin agonist corrects age-related changes in circadian response to environmental stimulus. Am. J. Physiol. Regul. Integr. Comp. Physiol.280, R1582–R1591 (2001).
   Web of Science ®Google Scholar
• Tuma J, Strubbe JH, Mocaer E, Koolhaas JM. S20098 affects the free-running rhythms of body temperature and activity and decreases light-induced phase delays of circadian rhythms of the rat. Chronobiol. Int.18, 781–799 (2001).
   PubMed Web of Science ®Google Scholar
• Ying SW, Rusak B, Delagrange P et al. Melatonin analogues as agonists and antagonists in the circadian system and other brain areas. Eur. J. Pharmacol.296, 33–42 (1996).
   PubMed Web of Science ®Google Scholar
• Shibata S, Cassone VM, Moore RY. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci. Lett.97, 140–144 (1989).
   PubMed Web of Science ®Google Scholar
• Stehle J, Vanecek J, Vollrath L. Effects of melatonin on spontaneous electrical activity of neurons in rat suprachiasmatic nuclei: an in vitro iontophoretic study. J. Neural. Transm.78, 173–177 (1989).
   PubMed Web of Science ®Google Scholar
• Wan Q, Man HY, Liu F et al. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat. Neurosci.2, 401–403 (1999).
   PubMed Web of Science ®Google Scholar
• Bertaina-Anglade V, Mocaer E, Drieu La Rochelle C. Antidepressant-like action of S20098 (agomelatine) in the learned helplessness test. Int. J. Neuropsychopharmacol.5(Suppl 1.), S65 (2002).
   Google Scholar
• Papp M, Gruca P, Boyer PA, Mocaer E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology28, 694–703 (2003).
   PubMed Web of Science ®Google Scholar
• Barden N, Shink E, Labbe M et al. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatry29, 908–916 (2005).
   PubMed Web of Science ®Google Scholar
• Fuchs E, Simon M, Schmelting B. Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system. Int. Clin. Psychopharmacol.21(Suppl. 1), S17–S20(2006).
   PubMed Web of Science ®Google Scholar
• Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol.47, 379–391 (1978).
   PubMed Web of Science ®Google Scholar
• Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol. Pharmacol.42, 991–995 (1992).
   PubMed Web of Science ®Google Scholar
• Wehr TA, Wirz-Justice A. Circadian rhythm mechanisms in affective illness and in antidepressant drug action. Pharmacopsychiatria15, 31–39 (1982).
   PubMedGoogle Scholar
• Fuchs E. Social stress in tree shrews as an animal model of depression: an example of a behavioral model of a CNS disorder. CNS Spectr.10, 182–190 (2005).
   PubMed Web of Science ®Google Scholar
• Griebel G, Perrault G, Sanger DJ. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology36, 793–802 (1997).
   PubMed Web of Science ®Google Scholar
• Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie60, 441–460 (2005).
   PubMed Web of Science ®Google Scholar
• Kahn D. Mood disorders. In: Textbook of Psychiatry. Cutler JG, Marcus ER (Eds). WB Saunders Company, PA, USA 33–63 (1999).
   Google Scholar
• Golombek DA, Martini M, Cardinali DP. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur. J. Pharmacol.237, 231–236 (1993).
   PubMed Web of Science ®Google Scholar
• Pierrefiche G, Zerbib R, Laborit H. Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors. Res. Commun. Chem. Pathol. Pharmacol.82, 131–142 (1993).
   PubMedGoogle Scholar
• Kopp C, Vogel E, Rettori M, Delagrange P, Misslin R. Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of mt1 and/or MT2 receptors in the regulation of emotional responsiveness. Neuropharmacology39, 1865–1871 (2000).
   PubMed Web of Science ®Google Scholar
• Cardinali DP, Gvozdenovich E, Kaplan MR et al. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuro. Endocrinol. Lett.23, 55–60 (2002).
   PubMed Web of Science ®Google Scholar
• Sharma A, Punhani T, Fone KC. Distribution of the 5-hydroxytryptamine2C receptor protein in adult rat brain and spinal cord determined using a receptor-directed antibody: effect of 5,7-dihydroxytryptamine. Synapse27, 45–56 (1997).
   PubMed Web of Science ®Google Scholar
• Lopez-Gimenez JF, Tecott LH, Palacios JM, Mengod G, Vilaro MT. Serotonin 5-HT (2C) receptor knockout mice: autoradiographic analysis of multiple serotonin receptors. J. Neurosci. Res.67, 69–85 (2002).
   PubMed Web of Science ®Google Scholar
• Millan MJ, Brocco M, Gobert A, Dekeyne A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade. Psychopharmacology (Berl.)177, 448–458 (2005).
   PubMed Web of Science ®Google Scholar
• Loiseau F, Le Bihan C, Hamon M, Thiebot MH. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Neuropsychopharmacology16, 417–428 (2006).
   Web of Science ®Google Scholar
• Naranjo-Rodriguez EB, Osornio AO, Hernandez-Avitia E, Mendoza-Fernandez V, Escobar A. Anxiolytic-like actions of melatonin, 5-metoxytryptophol, 5-hydroxytryptophol and benzodiazepines on a conflict procedure. Prog. Neuropsychopharmacol. Biol. Psychiatry24, 117–129 (2000).
   PubMed Web of Science ®Google Scholar
• Lowenstein P, Rosenstein RE, Cardinali DP. Melatonin reverses pinealectomy-induced decrease of benzodiazepine binding in rat cerebral cortex. Neurochem. Int.7, 675–681 (1985).
   PubMed Web of Science ®Google Scholar
• Rosenstein RE, Cardinali DP. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Res.398, 403–406 (1986).
   PubMed Web of Science ®Google Scholar
• Papp M, Litwa E, Gruca P, Mocaer E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav. Pharmacol.17, 9–18 (2006).
   PubMed Web of Science ®Google Scholar
• Bremner JD, Narayan M, Anderson ER et al. Hippocampal volume reduction in major depression. Am. J. Psychiatry157, 115–118 (2000).
   PubMed Web of Science ®Google Scholar
• MacQueen GM, Campbell S, McEwen BS et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl Acad. Sci. USA100, 1387–1392 (2003).
   PubMed Web of Science ®Google Scholar
• Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol. Psychiatry54, 338–352 (2003).
   PubMed Web of Science ®Google Scholar
• Fuchs E, Flugge G, Czeh B. Remodeling of neuronal networks by stress. Front. Biosci.11, 2746–2758 (2006).
   PubMed Web of Science ®Google Scholar
• Vythilingam M, Vermetten E, Anderson GM et al. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol. Psychiatry56, 101–112 (2004).
   PubMed Web of Science ®Google Scholar
• Eriksson PS, Perfilieva E, Bjork-Eriksson T et al. Neurogenesis in the adult human hippocampus. Nat. Med.4, 1313–1317 (1998).
   PubMed Web of Science ®Google Scholar
• Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci.20, 9104–9110 (2000).
   PubMed Web of Science ®Google Scholar
• Malberg JE, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr. Pharm. Des.11, 145–155 (2005).
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. A Neurotrophic model for stress-related mood disorders. Biol. Psychiatry59(12), 1116–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol. Psychiatry59, 1087–1096 (2006).
   PubMed Web of Science ®Google Scholar
• Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol. Psychiatry56, 570–580 (2004).
   PubMed Web of Science ®Google Scholar
• Morley-Fletcher S, Mairesse J, Mocaer E, Darnaudéry M, Villart O, Maccari S. Chronic treatment with agomelatine increases hippocampal cell proliferation in prenatally stressed rats. Society for Neuroscience, DC, USA (2003) (Abstract).
   Google Scholar
• Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol16, 93–100 (2006).
   PubMed Web of Science ®Google Scholar
• Hanoun N, Mocaer E, Boyer PA, Hamon M, Lanfumey L. Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology47, 515–526 (2004).
   PubMed Web of Science ®Google Scholar
• Clerc G. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int. Clin. Psychopharmacol.16, 145–151 (2001).
   PubMed Web of Science ®Google Scholar
• den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int. Clin. Psychopharmacol.21(Suppl. 1), S21–S24 (2006).
   Google Scholar
• Millan MJ, Gobert A, Rivet JM et al. Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur. J. Neurosci.12, 1079–1095 (2000).
   PubMed Web of Science ®Google Scholar
• Wichniak A, Riemann D, Kiemen A, Voderholzer U, Jernajczyk W. Comparison between eye movement latency and rapid eye movement (REM) sleep parameters in major depression. Eur. Arch. Psychiatry Clin. Neurosci.250, 48–52 (2000).
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Spiker DG, Coble PA et al. Sleep and treatment prediction in endogenous depression. Am. J. Psychiatry138, 429–434 (1981).
   PubMed Web of Science ®Google Scholar
• Cairns J, Waldron J, MacLean AW, Knowles JB. Sleep and depression: a case study of EEG sleep prior to relapse. Can. J. Psychiatry25, 259–263 (1980).
   PubMed Web of Science ®Google Scholar
• Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur. Neuropsychopharmacol.15(Suppl. 3), S419 (2005).
   Google Scholar
• Alapin I, Fichten CS, Libman E et al. How is good and poor sleep in older adults and college students related to daytime sleepiness, fatigue, and ability to concentrate? J. Psychosom. Res.49, 381–390 (2000).
   PubMed Web of Science ®Google Scholar
• Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep22(Suppl. 2), S347–S353 (1999).
   Google Scholar
• Brassington GS, King AC, Bliwise DL. Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years. J. Am. Geriatr. Soc.48, 1234–1240 (2000).
   PubMed Web of Science ®Google Scholar
• Walsh JK. Clinical and socioeconomic correlates of insomnia. J. Clin. Psychiatry65(Suppl. 8), 13–19 (2004).
   PubMed Web of Science ®Google Scholar
• Savard J, Laroche L, Simard S, Ivers H, Morin CM. Chronic insomnia and immune functioning. Psychosom. Med.65, 211–221 (2003).
   PubMed Web of Science ®Google Scholar
• Nicassio PM, Moxham EG, Schuman CE, Gevirtz RN. The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain100, 271–279 (2002).
   PubMed Web of Science ®Google Scholar
• Olie P, Emsley R. Confirmed clinical efficacy of agomelatine (25–50 mg) in major depression; two randomized, double-blind controlled studies. Eur. Neuropsychopharmacol.15(Suppl. 3), S416 (2005).
   Google Scholar
• Maestroni GJ, Cardinali DP, Esquifino AI, Pandi-Perumal SR. Does melatonin play a disease-promoting role in rheumatoid arthritis? J. Neuroimmunol.158, 106–111 (2005).
   PubMed Web of Science ®Google Scholar
• Mocaer E, Delalleau B, Boyer PA, de Bodinat C. Development of a new antidepressant: agomelatine. Med. Sci. (Paris)21, 888–893 (2005).
   PubMed Web of Science ®Google Scholar
• Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol.19, 67–85 (1999).
   PubMed Web of Science ®Google Scholar
• Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr. Womens Health Rep.2, 182–187 (2002).
   PubMedGoogle Scholar
• Rothschild AJ. Sexual side effects of antidepressants. J. Clin. Psychiatry61(Suppl. 11), 28–36 (2000).
   PubMed Web of Science ®Google Scholar
• Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry62(Suppl. 3), 10–21 (2001).
   PubMed Web of Science ®Google Scholar
• Kennedy SH. Sexual function in remitted depressed patients following agomelatine and venlafaxine XR treatment. Eur. Neuropsychopharmacology15(Suppl. 3), S440 (2005).
   Google Scholar
• Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol.19, 271–280 (2004).
   PubMed Web of Science ®Google Scholar